Share
A national clinical trial program will test promising new targeted therapies for pancreatic cancer, one of the deadliest forms of cancers of which more than 3000 cases are diagnosed annually in Australia.
The clinical trial program (MoST–P), led by researchers and clinicians at UNSW and the Garvan Institute, will provide patients with access to either targeted therapies matched to the genomic signature of their individual tumour, or targeted to the tumour environment.
UNSW Dean of Medicine & Health, Professor Vlado Perkovic said the grant could lead to better outcomes for pancreatic cancer patients and more personalised approaches to treatment.
“Our researchers constantly challenge existing knowledge on cancer and are at the forefront of advances in cancer research. The trial announced today is an exciting development in pancreatic cancer research and offers hope for the future for people affected by this terrible disease,” Prof. Perkovic said.